Feedback / Questions
Yescarta (axicabtagene ciloleucel) - Gilead
Yescarta: Protection of compound patent in US until 2031
(Gilead)
-
May 19, 2025 -
Annual Meeting Of Stockholders 2025
Patent
•
Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology
https://s29.q4cdn.com/585078350/files/doc_events/2024-Annual-Report-on-Form-10-K.pdf
May 19, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious